Double CAR T-Cell attack aims to stop Leukemia's return
NCT ID NCT07328503
Summary
This study is for children and adults (ages 3-65) with a type of blood cancer called B-cell acute lymphoblastic leukemia (ALL). The goal is to see if giving a second, different CAR T-cell treatment (targeting CD22) to people who are already in remission after their first CAR T-cell treatment (targeting CD19) can help keep the cancer from coming back for a longer time. Researchers will collect and modify the patient's own immune cells and then give them back after a short course of chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.